0001209191-22-000730.txt : 20220104 0001209191-22-000730.hdr.sgml : 20220104 20220104161957 ACCESSION NUMBER: 0001209191-22-000730 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220104 DATE AS OF CHANGE: 20220104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hansen Gwenn CENTRAL INDEX KEY: 0001817160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 22506239 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-03 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817160 Hansen Gwenn C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Scientific Officer Common Stock 2022-01-03 4 M 0 400 7.26 A 14597 D Common Stock 2022-01-03 4 M 0 1428 9.57 A 16025 D Common Stock 2022-01-03 4 S 0 1828 28.96 D 14197 D Employee Stock Option (right to buy) 7.26 2022-01-03 4 M 0 400 0.00 D 2030-02-26 Common Stock 400 67466 D Employee Stock Option (right to buy) 9.57 2022-01-03 4 M 0 1428 0.00 D 2030-05-27 Common Stock 1428 81905 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen 2022-01-04